Abstract: The disclosure relates to an adjuvant polypeptide effective at enhancing the immune response to an antigen crosslinked to the adjuvant polypeptide.

Abstract: An exhaust gas cooler assembly with an internally located bypass tube, spaced apart from and disposed within a core passage, with an exhaust gas inlet manifold directing exhaust gas to a plurality of cooling passages, or to the bypass tube by means of control valves. Further provided is a detachable valve cartridge with an actuator, with all moving components being included within the valve cartridge and actuator.

Abstract: We disclose antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against bacterial animal pathogens in particular bacterial pathogens of agriculturally important animal species and companion animals and including zoonotic Gram negative bacterial species.

Abstract: The disclosure relates to antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against human bacterial pathogens.

Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.

Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.

Abstract: Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.

Abstract: This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: We describe nucleic acid molecules that encode fusion polypeptides comprising GLP-1, or a receptor binding part thereof, linked directly or indirectly to a polypeptide that naturally binds GLP-1.

Abstract: We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins.

Abstract: We describe modified peptide linkers that function to link at least first and second polypeptides wherein said modified peptide linker comprises a motif for the addition of a sugar moiety.

Abstract: This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: An exhaust gas cooler assembly with an internally located bypass tube, spaced apart from and disposed within a core passage, with an exhaust gas inlet manifold directing exhaust gas to a plurality of cooling passages, or to the bypass tube by means of control valves. Further provided is a detachable valve cartridge with an actuator, with all moving components being included within the valve cartridge and actuator.

Abstract: The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.

Abstract: An exhaust gas cooler assembly (10) with an internally located bypass tube (50), spaced apart from and disposed within a core passage (60), with an exhaust gas inlet manifold (40) directing exhaust gas to a plurality of cooling passages (52, 54, 56, 58) or to the bypass tube (50) by means of control valves (42, 44). Further provided is a detachable valve cartridge (84) with an actuator (16), with all moving components being included within the valve cartridge (84) and actuator (16).

Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.